StockNews.com Begins Coverage on OpGen (NASDAQ:OPGN)

Equities research analysts at StockNews.com began coverage on shares of OpGen (NASDAQ:OPGNGet Free Report) in a research note issued to investors on Saturday. The brokerage set a “sell” rating on the medical research company’s stock.

OpGen Stock Performance

OPGN opened at $1.70 on Friday. OpGen has a 1 year low of $1.46 and a 1 year high of $9.90. The stock’s 50 day simple moving average is $1.87 and its 200 day simple moving average is $2.68.

OpGen (NASDAQ:OPGNGet Free Report) last issued its earnings results on Monday, August 19th. The medical research company reported ($1.18) earnings per share (EPS) for the quarter. The firm had revenue of $0.03 million for the quarter.

About OpGen

(Get Free Report)

OpGen, Inc, a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.

Read More

Receive News & Ratings for OpGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen and related companies with MarketBeat.com's FREE daily email newsletter.